AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26642810
Drug: Lapatinib (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1250 mg) combined with Gemcitabine (1000 mg/m2 on days 1 and 8)
Trial: 24690511
Drug: Group-based self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based self-management support programme (three monthly group sessions and a booster session three months later)
Trial: 23220811
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (1500 mg/day) plus exercise therapy
Trial: 18591457
Drug: Valsartan (low-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (low-, medium-, or high-dose)
Trial: 11295408
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g fosfomycin trometamol (single-dose)
Trial: 11295408
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ceftibuten (3-day course)
Trial: 7970503
Drug: Cyclical, sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical, sequential combination of tamoxifen and megestrol acetate (group B)
Trial: 28787507
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 µg/kg/min for 24 hours)
Trial: 26978493
Drug: D‐, L‐hopantenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐, L‐hopantenic acid (pantogam active) at a daily dose of 600 to 1200 mg for 28 days
Trial: 26978493
Drug: Standard cardiotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardiotropic hypotensive treatment (Control)
Trial: 24139424
Drug: Delayed-release dimethyl
RxNorm normalized name: dimethyl fumarate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release dimethyl fumarate (DR-DMF)
Trial: 24139424
Drug: Delayed-release dimethyl
RxNorm normalized name: dimethyl fumarate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release dimethyl fumarate (DR-DMF) with aspirin pretreatment
Trial: 20878292
Drug: Behavioral weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral weight loss treatment
Trial: 14618246
Drug: HYPER‐HES (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYPER‐HES (150 ml/m2 hypertonic NaCl (7.2%) 10% HES 200/0.5)
Trial: 14618246
Drug: HYPER‐DEX (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYPER‐DEX (150 ml/m2 hypertonic NaCl (7.2%) 10% dextran 60)
Trial: 14618246
Drug: HES (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES (250 ml/m2 10% HES 200/0.5 plus 400 ml/m2 NaCl 0.9%)
Trial: 14618246
Drug: DEX (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (250 ml/m2 10% dextran 40 plus 300 ml/m2 NaCl 0.9%)
Trial: 14618246
Drug: NACL (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACL (750 ml/m2 NaCl 0.9%)
Trial: 8694323
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL bupivacaine 0.5% (Group 1)
Trial: 8694323
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL saline (Group 2)
Trial: 31770235
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin D treatment
Trial: 31770235
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (not receiving treatment)
Trial: 27603001
Drug: Prolotherapy (intra-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy (intra- and extra-articular hypertonic dextrose injection)
Trial: 25132212
Drug: Alogliptin 12.5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg once daily (n = 880)
Trial: 25132212
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg once daily (n = 885)
Trial: 25132212
Drug: Glipizide 5
RxNorm normalized name: glipizide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide 5 mg once daily, titrated to a maximum of 20 mg (n = 874)
Trial: 22243959
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (mean 40.6 mg, SD 25 mg)
Trial: 22243959
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine alone (mean 14.4 mg, SD 9.4 mg)
Trial: 22243959
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of ketamine and morphine
Trial: 19858761
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (COMB) with risperidone and parent training (PT)
Trial: 19858761
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (MED)
Trial: 18281620
Drug: Multilevel botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel botulinum toxin A injections
Trial: 16168278
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 100 mg/day administered before bedtime
Trial: 16168278
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 100 mg/day administered on awakening
Trial: 12514662
Drug: Ineligible patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineligible patients not treated with reperfusion therapy (Control)
Trial: 8683232
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide phosphate (EP) at 125 mg/m2/d for 5 days
Trial: 8683232
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide phosphate (EP) at 150 mg/m2/d for 5 days
Trial: 8683232
Drug: Intravenous etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous etoposide (E) at 80 mg/m2 for 1 hour
Trial: 8683232
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide phosphate (EP)
Trial: 2054272
Drug: Propranolol (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (repeated administration)
Trial: 2054272
Drug: Verapamil and
RxNorm normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil and Propranolol (co-administered as single doses)
Trial: 2054272
Drug: Propranolol (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (repeated doses)
Trial: 2054272
Drug: Verapamil and
RxNorm normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil and Propranolol (single and repeated oral doses in combination)
Trial: 2054272
Drug: Verapamil and
RxNorm normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil and Propranolol (single doses in combination)
Trial: 30716803
Drug: Post-auricular subperiosteal
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-auricular subperiosteal injection of methylprednisolone combined with ginkgo biloba injection and mouse nerve growth factor
Trial: 30716803
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba injection and mouse nerve growth factor
Trial: 25245975
Drug: 30-min postload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-min postload glucose ≥ 165 mg/dL and 30-min C-peptide < 5 ng/mL
Trial: 7537664
Drug: Casodex 50
RxNorm normalized name: Casodex 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 50 mg/day
Trial: 7537664
Drug: Casodex 50
RxNorm normalized name: Casodex 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 50 mg/day for prostate cancer
Trial: 7537664
Drug: Casodex 50
RxNorm normalized name: Casodex 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 50 mg/day for benign prostatic hyperplasia (BPH)
Trial: 7537664
Drug: Casodex (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex (various doses)
Trial: 2686666
Drug: Supervised outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised outpatient physical therapy
Trial: 18070967
Drug: APL 600
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL 600 mg BID
Trial: 18070967
Drug: APL 800
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL 800 mg BID
Trial: 18070967
Drug: APL 200
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL 200 mg BID
Trial: 18070967
Drug: APL 400
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL 400 mg BID
Trial: 18070967
Drug: APL 800
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL 800 mg once a day
Trial: 17126779
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin (5 mL/kg)
Trial: 17126779
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (25 mL/kg)
Trial: 14566178
Drug: Low iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low iodine concentration (300 mg/mL) at slow flow rate (2.5 mL/s)
Trial: 14566178
Drug: Low contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low contrast concentration (300 mg/mL) at high flow rate (3.5 mL/s)
Trial: 14566178
Drug: High contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High contrast concentration (400 mg/mL) at high flow rate (3.5 mL/s)
Trial: 14566178
Drug: Approximately 1
RxNorm normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1 g iodine/s
Trial: 8900980
Drug: Hypovolemic condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypovolemic condition (induced by 30 mg furosemide)
Trial: 2049253
Drug: PGE1 (Prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (Prostaglandin E1) infused at doses ranging from 0.01 to 1.3 micrograms kg‐1 min‐1
Trial: 2049253
Drug: Control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control saline solution (isotonic)
Trial: 30412032
Drug: HYP-CHO (carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYP-CHO (carbohydrate solution in hypoxia)
Trial: 18495372
Drug: High-tech external
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-tech external beam therapy (EBT)
Trial: 12656706
Drug: Web-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based self-help program with e-mail support + weekly individual telephone calls
Trial: 11023140
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (goal HbA(1c) 7.1%)
Trial: 11023140
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (goal HbA(1c) 9.1%)
Trial: 9083166
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone (124 +/- 22 mg per day)
Trial: 9083166
Drug: Controlled-release hydromorphone
RxNorm normalized name: hydromorphone Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release hydromorphone (30 +/- 6 mg per day)
Trial: 3789915
Drug: High-dose doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose doxorubicin therapy
Trial: 3789915
Drug: Low-dose doxorubicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxorubicin therapy
Trial: 30075780
Drug: Interactive power
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interactive power toothbrush (IPT) - Oral-B® ProfessionalCare 6000 with Bluetooth
Trial: 30075780
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (MT) - Oral-B® Indicator soft manual toothbrush
Trial: 24780850
Drug: Intradiskal methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiskal methylene blue injection
Trial: 18334911
Drug: Iloperidone 12
RxNorm normalized name: iloperidone 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone 12 mg/d
Trial: 18334911
Drug: Iloperidone 4-8
RxNorm normalized name: iloperidone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone 4-8 mg/d
Trial: 18334911
Drug: Iloperidone 10-16
RxNorm normalized name: iloperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone 10-16 mg/d
Trial: 18334911
Drug: Iloperidone 20-24
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone 20-24 mg/d
Trial: 18334911
Drug: Risperidone 4-8
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4-8 mg/d
Trial: 8723448
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G (3 g every 6 hours)
Trial: 8723448
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg every 24 hours)
Trial: 1328358
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (5-10 mg norethynodrel with mestranol 0.075-0.15 mg or conjugated estrogens 0.625 mg)
Trial: 3526804
Drug: Tinidazole 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 1,600 mg i.v. preoperatively
Trial: 26983925
Drug: Lidocaine cream
RxNorm normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine cream applied from wrist to shoulder
Trial: 26983925
Drug: Neutral cream
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral cream (placebo) applied to the same skin area
Trial: 26983925
Drug: Neutral cream
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral cream (placebo)
Trial: 24106340
Drug: Active doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active doxycycline (100 mg BID for 7 days)
Trial: 21880289
Drug: High on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High on-treatment platelet reactivity (HOPR) defined as OPR ≥235 P2Y12 reactivity units
Trial: 21880289
Drug: Normal on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal on-treatment platelet reactivity (non-HOPR)
Trial: 8005278
Drug: i.v. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration of 50 g of human albumin diluted in 500 mL of sodium chloride 0.9%
Trial: 8005278
Drug: sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium chloride 0.9% solution
Trial: 2686741
Drug: Cefadroxil 1
RxNorm normalized name: CEFADROXIL 1GM TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1 g twice daily
Trial: 2686741
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg three times a day
Trial: 12454840
Drug: Entecavir 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.1 mg/day
Trial: 12454840
Drug: Entecavir 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.1 mg/day and 0.5 mg/day
Trial: 27659102
Drug: Self-referral to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-referral to inpatient treatment (contract for self-referral, maximum 5 days, quarantine time of 14 days between stays)
Trial: 24797321
Drug: ADH1B*2/*2 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADH1B*2/*2 group with 0.25 g/kg EtOH
Trial: 24797321
Drug: ADH1B*2/*2 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADH1B*2/*2 group with 0.5 g/kg EtOH
Trial: 24797321
Drug: ADH1B*1/*2 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADH1B*1/*2 group at 0.5 g/kg EtOH
Trial: 22928903
Drug: Early dental
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early dental treatment for severe dental caries
Trial: 22928903
Drug: Control (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (regular dental treatment)
Trial: 20361072
Drug: SCM‐III symbiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCM‐III symbiotic mixture, 10 ml three times a day
Trial: 10210074
Drug: Semitendinosus and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semitendinosus and gracilis (ST/G)
Trial: 7610222
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support therapy
Trial: 2379533
Drug: Furegrelate 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furegrelate 800 mg
Trial: 2379533
Drug: Furegrelate 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furegrelate 1600 mg
Trial: 2379533
Drug: Furegrelate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furegrelate (all doses)
Trial: 2379533
Drug: Furegrelate (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furegrelate (higher doses)
Trial: 28647451
Drug: Mindfulness, cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness, cognitive based therapy
Trial: 12164031
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral iron supplementation (100 mg elemental iron)
Trial: 12164031
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly oral iron supplementation (100 mg elemental iron)
Trial: 12164031
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral iron supplementation (100 mg elemental iron)
Trial: 27354202
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill with conditioned stimulus (novel-tasting drink)
Trial: 20216117
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) dosing regimens (fixed and concentration-controlled)
Trial: 14696994
Drug: Resonance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resonance therapy (RT; n = 19)
Trial: 15220165
Drug: Epidural oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural oxycodone 6 mg day(‐1)
Trial: 15220165
Drug: Epidural oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural oxycodone 12 mg day(‐1)
Trial: 15220165
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 6 mg day(‐1)
Trial: 3290622
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin treatment (UCT)
Trial: 1375801
Drug: Risperidone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (12 mg daily)
Trial: 1375801
Drug: Haloperidol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10 mg daily)
Trial: 7511740
Drug: enalapril, lisinopril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril, lisinopril, or perindopril (ACE inhibitors) for 8-12 weeks
Trial: 7511740
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor monotherapy
Trial: 28593720
Drug: Phytoestrogen-rich natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoestrogen-rich natural preparation Karinat
Trial: 26248676
Drug: Immediate vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate vaccination with rVSV‐ZEBOV (one dose of 2×10^7 plaque‐forming units, administered intramuscularly)
Trial: 23065050
Drug: 27-G Whitacre
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 27-G Whitacre spinal needle